|
1. Gaffar NR, Valand N, Girija UV. Candidiasis: Insights into Virulence Factors, Complement Evasion and Antifungal Drug Resistance. Microorganisms. 2025; 13:272. doi: 10.3390/microorganisms13020272. 2. Tsui C, Kong EF, Jabra-Rizk MA. Pathogenesis of Candida albicans biofilm. Pathog Dis. 2016;74: ftw018. doi: 10.1093/femspd/ftw018. 3. Parambath S, Dao A, Kim HY, Zawahir S, Alastruey Izquierdo A, Tacconelli E, et al. Candida albicans—A systematic review to inform the World Health Organization Fungal Priority Pathogens List. Med Mycol. 2024;62:myae045. doi: 10.1093/mmy/myae074. 4. Talapko J, Juzbašić M, Matijević T, Pustijanac E, Bekić S, Kotris I, et al. Candida albicans—the virulence factors and clinical manifestations of infection. J Fungi. 2021;7:79. doi: 10.3390/jof7020079. 5. Abdullah AT, Al-Hawash AB, Dhari FM. Evaluation of The Effect of Aqueous Garlic Extract Against Candida Albicans and Candida Krusei Isolated From The Vagina. IJHSM. 2025;2:10.21070/ijhsm. doi: 10.21070/ijhsm.v2i1.80. 6. Pristov K, Ghannoum M. Resistance of Candida to azoles and echinocandins worldwide. Clin Microbiol Infect. 2019;25:792-8. doi: 10.1016/j.cmi.2019.03.028. 7. Erfaninejad M, Zarei Mahmoudabadi A, Maraghi E, Hashemzadeh M, Fatahinia M. Epidemiology, prevalence, and associated factors of oral candidiasis in HIV patients from southwest Iran in post-highly active antiretroviral therapy era. Front Microbiol. 2022;13:983348. doi: 10.3389/fmicb.2022.983348. 8. Maryoush SS, Ajah HA, Abdulrazaq RA. Detection of Some Virulence Factors from Candida spp. Isolated from Vaginal and Oral Candidiasis in Iraqi Patients. Clin Lab. 2025;71 doi: 10.7754/Clin.Lab.2024.240304. 9. Sachivkina N, Podoprigora I, Bokov D. Morphological characteristics of Candida albicans, Candida krusei, Candida guilliermondii, and Candida glabrata biofilms, and response to farnesol. Vet World. 2021;14:1608. doi: 10.14202/vetworld.2021.1608-1614. 10. Rafiq NB. Candidiasis. StatPearls . StatPearls Publishing; 2023. 11. Kumar A, Yadav B, Roy A, Mishra P, Poluri KM, Gupta P. Biochemical Insights into synergistic Candida Biofilm disintegrating ability of p-cymene inclusion complex and miconazole. Eur J Pharmacol. 2025:177365. doi: 10.1016/j.ejphar.2025.177365. 12. Gulati M, Nobile CJ. Candida albicans biofilms: development, regulation, and molecular mechanisms. Microbes Infect. 2016;18:310-21. doi: 10.1016/j.micinf.2016.01.002. 13. Xia C, Liu R, Zhang S, Shen J, Wang Z. Fluconazole-induced changes in azole resistance and biofilm production in Candida glabrata in vitro. Diagn Microbiol Infect Dis. 2025;111:116683. doi: 10.1016/j.diagmicrobio.2025.116683. 14. Zarnowski R, Horton MV, Johnson CJ, Vang PC, Uram J, Fernando LDP, et al. Dual function of Candida auris mannosyltransferase, MTN5, in biofilm community protection from antifungal therapy and the host. mBio. 2025:e00346-25. doi: 10.1128/mbio.00346-25. 15. Ponde NO, Lortal L, Ramage G, Naglik JR, Richardson JP. Candida albicans biofilms and polymicrobial interactions. Crit Rev Microbiol. 2021;47:91-111. doi: 10.1080/1040841X.2020.1843400. 16. Høiby N, Bjarnsholt T, Moser C, Bassi G, Coenye T, Donelli G, et al. ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. Clin Microbiol Infect. 2015;21:S1-S25. doi: 10.1016/j.cmi.2014.10.024. 17. Dhasarathan P, AlSalhi MS, Devanesan S, Subbiah J, Ranjitsingh A, Binsalah M, et al. Drug resistance in Candida albicans isolates and related changes in the structural domain of Mdr1 protein. J Infect Public Health. 2021;14:1848-53. doi: 10.1016/j.jiph.2021.11.002. 18. Sardi J, Scorzoni L, Bernardi T, Fusco-Almeida A, Mendes Giannini MJS. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2013;62:10-24. doi: 10.1099/jmm.0.045054-0. 19. Ding X, Liu Z, Su J, Yan D. Human serum inhibits adhesion and biofilm formation in Candida albicans. BMC Microbiol. 2014;14:1-9. doi: 10.1186/1471-2180-14-80. 20. Weerasekera MM, Wijesinghe GK, Jayarathna TA, Gunasekara CP, Fernando N, Kottegoda N, et al. Culture media profoundly affect Candida albicans and Candida tropicalis growth, adhesion and biofilm development. Mem Inst Oswaldo Cruz. 2016;111:697-702. doi: 10.1590/0074-02760160294. 21. Costa PdS, Prado A, Bagon NP, Negri M, Svidzinski TIE. Mixed fungal biofilms: From mycobiota to devices, a new challenge on clinical practice. Microorganisms. 2022;10:1721. doi: 10.3390/microorganisms10091721. 22. Pereira R, dos Santos Fontenelle RO, De Brito E, De Morais S. Biofilm of Candida albicans: formation, regulation and resistance. J Appl Microbiol. 2021;131:11-22. doi: 10.1111/jam.14949. 23. Ramage G, Vande Walle K, Wickes BL, López-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother. 2001;45:2475-9. doi: 10.1128/AAC.45.9.2475-2479.2001. 24. Weerasekera M. Culture media profoundly affect Candida albicans and Candida tropicalis growth, adhesion and biofilm development. Mem Inst Oswaldo Cruz. 2016;111:697-702. doi: 10.1590/0074-02760160294. 25. Abdulghani M, Zore G. Optimization of in vitro Biofilm Growth of Candida albicans. Indian J Microbiol. 2025;65:1361-5. doi: 10.1007/s12088-024-01220-x. 26. Arzmi MH, Alnuaimi AD, Dashper S, Cirillo N, Reynolds EC, McCullough M. Polymicrobial biofilm formation by Candida albicans, Actinomyces naeslundii, and Streptococcus mutans is Candida albicans strain and medium dependent. Med Mycol. 2016;54:856-64. doi: 10.1093/mmy/myw042. 27. Arévalo-Jaimes BV, Admella J, Blanco-Cabra N, Torrents E. Culture media influences Candida parapsilosis growth, susceptibility, and virulence. Front Cell Infect Microbiol. 2023; 13:1323619. doi: 10.3389/fcimb.2023.1323619. 28. Tan Y, Leonhard M, Ma S, Schneider-Stickler B. Influence of culture conditions for clinically isolated non-albicans Candida biofilm formation. J Microbiol Methods. 2016;130:123-8. doi: 10.1016/j.mimet.2016.09.011.
|
